Briefing: genetics and cancer research
Advances in genetics and proteomics offer the possibility that existing and new treatments can be tailored to individual patients. The UK should take full advantage of emerging genetic technologies and the benefits for patients that they hold.
Applying these technologies promises the dual benefits of avoiding unnecessary treatment in patients who are less likely to respond to a particular drug, and targeting treatments more closely to those who will benefit.
Britain is currently at the leading edge of advances in genetic technologies. To achieve the full benefits that these may bring requires large-scale studies. As it is unlikely that these will be undertaken by the pharmaceutical industry we ask that a commitment is made to support the provision of public money to fund clinical investigators conducting these studies. The economic and social benefits make this a worthwhile investment in the longer term.
Public confidence in the advances of genetic research is important. The public will need to understand the difference between research into the genetics of predisposition to disease and the genetics of diagnosis and prognosis. Legitimate concerns in one area might otherwise seriously impede progress in others.
Appropriate and balanced legislation is necessary to ensure that people do not suffer genetic discrimination when applying for life insurance, mortgages and jobs. All patients treated within the NHS should have the right to choose to take genetic tests free from the fear of future genetic discrimination.
A - Z index
Contact us
Donate now
Glossary
Print this page